Hilleman Laboratories
Dr. N Erlyani Abd Hamid has a diverse work experience spanning over several years. Dr. N Erlyani'smost recent role is with Hilleman Laboratories, where they have been working since 2021. In their position as Program Strategy & Business Operations, they are responsible for coordinating and executing key management forums, ensuring smooth business processes, shaping the company's strategy roadmap, and engaging with stakeholders and the Board.
Prior to their current role, Dr. Hamid worked at A*STAR - Agency for Science, Technology and Research as the Head from 2015 to 2021. Before that, they were a Research Fellow at the Genome Institute of Singapore from 2013 to 2015. Dr. N Erlyani also had research attachments at the Institute of Bioengineering & Nanotechnology in 2006 and 2005.
Through their various roles, Dr. Hamid has gained experience in strategic planning, research, and operations management.
Dr. N Erlyani Abd Hamid received a Doctor of Philosophy (PhD) in Stem Cell & Developmental Biology from the NUS Graduate School for Integrative Sciences & Engineering, from 2008 to 2013. Prior to that, they completed a Bachelor of Science (B.Sc. Hons) in Biomedical Science at the National University of Singapore from 2004 to 2008. Dr. N Erlyani also attended Raffles Institution from 2002 to 2003, studying Biology, General. Dr. Hamid completed their secondary education at Raffles Girls' School from 1998 to 2001.
Furthermore, they have obtained additional certifications, including Design Thinking for Business Innovation from Singapore Polytechnic in March 2020, and a Certificate in Commercial Law & Tech Transfer from Temasek Polytechnic in May 2016.
This person is not in any teams
This person is not in any offices
Hilleman Laboratories
Hilleman Laboratories is a non-profit and global welfare organization proprietor of a research and vaccine organization created to fill gaps in reduced environments. By utilizing advanced biotechnology with a focus on thermo-stability, ease of administration decreased footprint and economy, the firm aims to develop an innovative vaccinationplatform and offer affordable vaccines for unusual diseases to the general public.